Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies

Jennifer Woyach, MD, Deborah M. Stephens, DO, Ian W. Flinn, MD PhD, Seema A. Bhat, MD, Ronald E. Savage, Feng Chai, MD, Sudharshan Eathiraj, PhD, Lindsey Granlund, Lyndsey A. Szuszkiewicz, Brian Schwartz, MD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 4298.

https://doi.org/10.1182/blood-2019-127260

Published: 2019

Journal Articles

Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Beth A. Christian, MD, Ying Huang, MS, MA, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Jonathan E Brammer, MD, Narendranath Epperla, MDMS, Samantha Jaglowski, MDMPH, Basem M. William, MRCP,MD, Farrukh T. Awan, MD, Kami J. Maddocks, MD, Kristie A. Blum, MD

Blood (2019) 134 (Supplement_1): 4082.

https://doi.org/10.1182/blood-2019-126242

Published: 2019

Journal Articles

First-in-Human Study of the EZH1/2 Dual Inhibitor Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) - Updated Results Focusing on Adult T-Cell Leukemia-Lymphoma (ATL)

Satoko Morishima, MD PhD, Kenji Ishitsuka, MD PhD, Koji Izutsu, MD PhD, Shigeru Kusumoto, MD PhD, Junya Makiyama, MD PhD, Atae Utsunomiya, MD, Kisato Nosaka, MD PhD, Takashi Ishida, MD PhD, Yoshitaka Imaizumi, MD PhD, Nobuhiko Yamauchi, MD, Kazushi Araki, DVM, PhD, Nobuaki Adachi, PhD, Tomonari Yamashita, Ryo Atsumi, PhD, Kunihiro Tsukasaki, MD PhD, Kensei Tobinai, MD PhD

Blood (2019) 134 (Supplement_1): 4025.

https://doi.org/10.1182/blood-2019-125507

Published: 2019

Journal Articles

A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4033.

https://doi.org/10.1182/blood-2019-124179

Published: 2019

Journal Articles

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome

Sangmin Lee, MD, Bhavana Bhatnagar, DO, Sanjay R Mohan, MD MSCI, William T. Senapedis, Jr., Erkan Baloglu, PhD, Hongwei Wang, MD, Jatin J. Shah, MD, Sharon Shacham, PhD MBA, Michael G. Kauffman, MD PhD

Blood (2019) 134 (Supplement_1): 2997.

https://doi.org/10.1182/blood-2019-124136

Published: 2019

Journal Articles

Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia

Amer M. Zeidan, MBBS, MHS, Michael W. Schuster, MD, Jürgen Krauter, MD, Johan A. Maertens, MD PhD, Emmanuel Gyan, MD PhD, Magalie Joris, MD, Tobias F Menne, MD PhD FRCPath, Paresh Vyas, MD PhD, Weidong Wendy Ma, Ashleigh O'Connell, Mirjana Zeremski, MD, Arthur Kudla, Geoffrey Chan, MD, Mikkael A. Sekeres, MD MS

Blood (2019) 134 (Supplement_1): 3916.

https://doi.org/10.1182/blood-2019-124034

Published: 2019

Journal Articles

Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma

Blood (2019) 134 (Supplement_1): 1905.

https://doi.org/10.1182/blood-2019-132035

Published: 2019

Journal Articles

A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse

Andrew Kent, MD PhD, Sumithira Vasu, MDMBBS, Derek Schatz, Natalie Monson, Steven Devine, MD, Clayton Smith, MD, Jonathan A Gutman, MD, Daniel A Pollyea, MD

Blood (2019) 134 (Supplement_1): 1311.

https://doi.org/10.1182/blood-2019-127418

Published: 2019

Journal Articles

Diet Quality of Long-Term Allogeneic and Autologous Stem Cell Transplant (HCT) Survivors

Nosha Farhadfar, MD, Debra Lynch Kelly, PhD, Lacey E. Mead, BS, Shalini Nair, Randy A. Brown, MD, John W. Hiemenz, MD, Jack W. Hsu, MD, Hemant S. Murthy, MD, W. Stratford May, MD PhD, John R. Wingard, MD, Wendy J Dahl, PhD

Blood (2019) 134 (Supplement_1): 4565.

https://doi.org/10.1182/blood-2019-127648

Published: 2019

Journal Articles

A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

Mikkael A. Sekeres, MD MS, Michael W. Schuster, MD, Magalie Joris, MD, Jürgen Krauter, MD, Johan A. Maertens, MD PhD, Emmanuel Gyan, MD PhD, Tibor Kovacsovics, MD, Amit Verma, MBBS, Paresh Vyas, MD PhD, Eunice S. Wang, MD, Weidong Wendy Ma, Mirjana Zeremski, MD, Arthur Kudla, Geoffrey Chan, MD, Amer M. Zeidan, MBBS, MHS

Blood (2019) 134 (Supplement_1): 177.

https://doi.org/10.1182/blood-2019-124050

Published: 2019

Journal Articles

Combined Modality Low-Dose Radiation Therapy (2 Gy x 2) and Single-Agent Rituximab Immunotherapy in the Treatment of Indolent Non-Hodgkin Lymphoma

Samantha Brocklehurst, Neil Desai, MD MHS, Jennifer L Shah, MD, Syed Rizvi, MD, Praveen Ramakrishnan Geethakumari, MD, Kiran A Kumar, MD MBA

Blood (2019) 134 (Supplement_1): 5262.

https://doi.org/10.1182/blood-2019-131246

Published: 2019

Journal Articles

Results from a Phase Ib Evaluation of Tazemetostat (EPZ-6438) in Combination with R-CHOP in Poor Prognosis Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): a Lysa Study

Clementine Sarkozy, MD, Franck Morschhauser, MD, Jean-Marie Michot, MD, Benjamin Suttle, Lionel Karlin, MD, Steven LE Gouill, MD PhD, Fabrice Jardin, MD PhD, Herve Tilly, MD, Charles Herbaux, MD, Gilles Andre Salles, Vincent Ribrag, MD

Blood (2018) 132 (Supplement 1): 4191.

https://doi.org/10.1182/blood-2018-99-113193

Published: 2018

Journal Articles

Single Institution Phase 1 Study on Combination Therapy of Midostaurin and Panobinostat in Acute Myeloid Leukemia - the Interim Report

Chin-Hin NG, MD MRCP, FRPATH, Liang Piu Koh, MBBS, MRCP, Melissa Ooi, MB BCh, BAO, MRCP(I), FRCPath, PhD, Wei Ying Jen, MA, Wee Joo Chng, MB ChB, PhD FRCP(UK), FRCPath, FAMS

Blood (2018) 132 (Supplement 1): 5237.

https://doi.org/10.1182/blood-2018-99-120327

Published: 2018

Journal Articles

Ciraparantag Safely and Effectively Reverses Apixaban and Rivaroxaban in Age-Matched Healthy Volunteers As Measured By Whole Blood Clotting Time

Bryan Laulicht, PhD, Sasha Bakhru, PhD, Solomon Steiner, PhD, Jack Ansell, MD

Blood (2018) 132 (Supplement 1): 987.

https://doi.org/10.1182/blood-2018-99-116754

Published: 2018

Journal Articles

Glasdegib in Addition to Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia: Safety Analysis of Glasdegib 'On Target' Adverse Events

Jorge E. Cortes, MD, Cristina Papayannidis, Catriona Jamieson, MD PhD, Gary J. Schiller, MD, Anna Candoni, MD, Brian Leber, MD, Claudia D. Baldus, MD, José A. Pérez-Simón, MD PhD, Weidong Wendy Ma, Corrado Gallo Stampino, Ashleigh O'Connell, Mirjana Zeremski, MD, Geoffrey Chan, MD, Mikkael A. Sekeres, MD MS

Blood (2018) 132 (Supplement 1): 2732.

https://doi.org/10.1182/blood-2018-99-110934

Published: 2018

Journal Articles

Dysgeusia Is Associated with Higher Melphalan Pharmacokinetic Levels and Results in Poorer Caloric Intake and Worse Symptom Burden after Autologous Stem Cell Transplantation for Multiple Myeloma

Michael Scordo, MD, Gunjan L. Shah, MD, Elaina V. Preston, PA-C, MPH, Natasia Rodriguez, BSN, RN, Andrew Lin, PharmD, BCOP, Molly Maloy, MS, Brooke Mastrogiacomo, BS, Dean Carlow, MD PhD, Ryan Schofield, MS, Andrea Knezevic, MS, Sean M Devlin, PhD, Heather J. Landau, MD, David J. Chung, MD PhD, Jonathan U. Peled, MD PhD, Marissa L. Buchan, MS, Sergio Giralt, MD

Blood (2018) 132 (Supplement 1): 2136.

https://doi.org/10.1182/blood-2018-99-114715

Published: 2018

Journal Articles

Hedgehog Pathway Inhibitor for Treatment of Steroid-Refractory Sclerodermatous Chronic Graft-Versus-Host Disease (GVHD)

Ridhi Gupta, MD, Abdulwahab Albabtain, MD, Sally Arai, MD, Bernice Kwong, MD, Wen-Kai Weng, MD PhD

Blood (2018) 132 (Supplement 1): 3409.

https://doi.org/10.1182/blood-2018-99-113915

Published: 2018

Journal Articles

First-in-Human Study of the EZH1/2 Dual Inhibitor DS-3201b in Patients with Relapsed or Refractory Non-Hodgkin Lymphomas — Preliminary Results

Dai Maruyama, MD PhD, Kensei Tobinai, MD PhD, Shinichi Makita, MD, PhD, Takashi Ishida, MD PhD, Shigeru Kusumoto, MD, Kenji Ishitsuka, MD PhD, Makoto Yoshimitsu, MD PhD, Yoshitaka Imaizumi, MD PhD, Yasushi Sawayama, MD, PhD, Shogo Takeuchi, MD, Atae Utsunomiya, MD, PhD, Kunihiro Tsukasaki, MD PhD, Sumiaki Fujitani, MSc, Kazushi Araki, D.V.M., PhD

Blood (2017) 130 (Supplement 1): 4070.

https://doi.org/10.1182/blood.V130.Suppl_1.4070.4070

Published: 2017

Journal Articles

Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Vs Ld in Patients with Newly Diagnosed Multiple Myeloma: Phase 2, Randomized, Open-Label Study in Japan

Naoki Takezako, MD PhD, Kensuke Ohta, MD PhD, Hiroshi Handa, MD PhDChief Division, Mitsuo Hori, MD PhD, Gen Kinoshita, Suresh Shelat, Masafumi Miyoshi, Kohmei Kubo

Blood (2017) 130 (Supplement 1): 434.

https://doi.org/10.1182/blood.V130.Suppl_1.434.434

Published: 2017

Journal Articles

Phase 1b Results of a Study to Assess the Efficacy and Safety of Vismodegib in Combination with Ruxolitinib in Patients with Intermediate- or High-Risk Myelofibrosis

Stephen Couban, MDBSc, Giulia Benevolo, William Donnellan, Jennifer Cultrera, Steffen Koschmieder, Srdan Verstovsek, MD PhD, Gregory Hooper, Christian Hertig, Maneesh Tandon, Natalie Dimier, Ian Templeton, Francesco Passamonti

Blood (2017) 130 (Supplement 1): 4179.

https://doi.org/10.1182/blood.V130.Suppl_1.4179.4179

Published: 2017

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies

Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

First-in-Human Study of the EZH1/2 Dual Inhibitor Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) - Updated Results Focusing on Adult T-Cell Leukemia-Lymphoma (ATL)

A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome

Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia

Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma

A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse

Diet Quality of Long-Term Allogeneic and Autologous Stem Cell Transplant (HCT) Survivors

A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

Combined Modality Low-Dose Radiation Therapy (2 Gy x 2) and Single-Agent Rituximab Immunotherapy in the Treatment of Indolent Non-Hodgkin Lymphoma

Results from a Phase Ib Evaluation of Tazemetostat (EPZ-6438) in Combination with R-CHOP in Poor Prognosis Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): a Lysa Study

Single Institution Phase 1 Study on Combination Therapy of Midostaurin and Panobinostat in Acute Myeloid Leukemia - the Interim Report

Ciraparantag Safely and Effectively Reverses Apixaban and Rivaroxaban in Age-Matched Healthy Volunteers As Measured By Whole Blood Clotting Time

Glasdegib in Addition to Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia: Safety Analysis of Glasdegib 'On Target' Adverse Events

Dysgeusia Is Associated with Higher Melphalan Pharmacokinetic Levels and Results in Poorer Caloric Intake and Worse Symptom Burden after Autologous Stem Cell Transplantation for Multiple Myeloma

Hedgehog Pathway Inhibitor for Treatment of Steroid-Refractory Sclerodermatous Chronic Graft-Versus-Host Disease (GVHD)

First-in-Human Study of the EZH1/2 Dual Inhibitor DS-3201b in Patients with Relapsed or Refractory Non-Hodgkin Lymphomas — Preliminary Results

Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Vs Ld in Patients with Newly Diagnosed Multiple Myeloma: Phase 2, Randomized, Open-Label Study in Japan

Phase 1b Results of a Study to Assess the Efficacy and Safety of Vismodegib in Combination with Ruxolitinib in Patients with Intermediate- or High-Risk Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only